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6/j.bPatients with severe aplastic anemia (SAA) over 40 years of age are often not offered treatment with hema-
topoietic cell transplantation (HCT) because of concerns about treatment-related morbidity or mortality. To
evaluate this risk, we analyzed outcomes after allogeneic HCT fromHLA-identical sibling donors for all older
patients with SAA at our center since 1988. The 23 consecutive patients ranged in age from 40 to 68 years.
The conditioning regimen was cyclophosphamide (200 mg/kg) and horse antithymocyte globulin. Methotrex-
ate and cyclosporine were given for postgrafting immunosuppression. The cumulative incidences of grades II,
III, and IV acute graft-versus-host-disease were 30%, 4%, and 0%, respectively; that for chronic GVHD was
26%.With a median follow-up of 9.1 years, overall survival was 65%. Documented infections within 1 month
before HCT were significantly associated with risk of early treatment-related mortality (P\ .001). The
median time to discontinuation of posttransplant immunosuppression was 6.2 (range: 5.9-92.0) months.
Three patients developed superficial basal cell carcinoma between 5.5 and 15 years after HCT. Our data favor
a practice of extending HLA-identical sibling HCT for treatment of SAA in patients older than 40 years of age
who are without significant medical comorbidities.
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bmt.2010.04.005without excess blasts [1]. Hematopoietic cell transplan-
tation (HCT) from a human leukocyte antigen (HLA)-
matched donor offers definitive curative treatment
[2,3]. For younger SAA patients, long-term survival
of approximately 90% has been observed after bone
marrow (BM) transplantation from HLA-identical
siblings after conditioning with cyclophosphamide
and antithymocyte globulin (Cy 1 ATG) followed by
postgrafting immunosuppression with methotrexate
and cyclosporine (MTX 1 CsA) [2,4-6]. Immune
suppressive therapy (IST) with ATG and CsA has
been used successfully for SAA patients who were not
considered candidates for HCT or lack a suitable
donor [7-12].
Many transplant center guidelines restrict alloge-
neic HCT to SAA patients younger than 40 years of
age because of concern about the increased risk of
treatment-related morbidity and mortality in older
patients [13-15]. In a previous study from our
Center, long-term survival afterHLA-matched related
HCT for SAA patients older than 40 years of age was
36% and not significantly different from that of1411
Table 1. Pretransplant Characteristics of Patients in the
Study
Patients, n 23
Age, in years, median (range) 49 (40-68)
Sex (F/M), n 11/12
Donor-recipient sex mismatched, n (%) 11 (48%)
Major ABO mismatched, n (%) 4 (17%)
ANC on admission, median cells/mL (range) 160 (0-1900)
Platelet count on admission, median  109/L (range) 7.5 (1-49)
Hematocrit on admission, median % (range) 22 (16-30)
Patients with very severe aplastic anemia (ANC
<200 cells/mL), n (%)
15 (65%)
Transfused patients prior to HCT
Red blood cell, n (%) 23 (100%)
Platelet, n (%) 23 (100%)
History of pre-HCT immune suppressive treatment, n (%) 11 (48%)
Median duration of aplastic anemia prior to HCT,
months (range)
3 (1-46)
CMV serostatus of patients
Recipient +/donor +, n (%) 13 (57%)
Recipient +/donor –, n (%) 7 (30%)
Recipient –/donor +, n (%) 2 (9%)
Recipient –/donor –, n (%) 1 (4%)
n indicates number of patients; F, female; M, male; ABO, major blood
group antigen type; ANC, absolute neutrophil count; HCT, hematopoi-
etic cell transplantation; CMV, cytomegalovirus.
1412 Biol Blood Marrow Transplant 16:1411-1418, 2010D. Sangiolo et al.patients treated with IST alone [16]. An analysis by the
European Bone Marrow Transplantation (EBMT)
SAA working party showed that IST was superior to
HCT for SAA patients older than 40 years of age
[17]. More recently, an EBMT analysis showed that
with Cy 200 mg/kg with or without ATG condition-
ing, overall survival (OS) at 4 years after HCT was
60% for SAA patients older than 30 years of age; for
a smaller cohort of patients receiving a fludarabine
(Flu)-based regimen, OS at 4 years was 77% [18].
These results suggest that the outcome of HCT for
treatment of SAA in older patients has improved in
recent years. Despite the improved survival, concern
persists that the conventional Cy 200 mg/kg condi-
tioning regimen may cause excessive toxicity in older
SAA patients. Most patients included in the historical
studies did not receive what is currently considered
the optimal SAA transplant regimen, which consists
of Cy 1 ATG conditioning and MTX 1 CsA post-
grafting immunosuppression.
In the current study we report outcomes for all
consecutive patients with SAA above the age of 40
year who had HCT from HLA-identical siblings at
a single transplant center from 1988 to 2008. We
also identify new pretransplant risk factors that may
help to select more suitable HCT candidates among
older patients with SAA.PATIENTS AND METHODS
We retrospectively reviewed the clinical records of
all 23 consecutive SAA patients who were older than 40
years and had HCT from HLA-identical siblings at the
Fred Hutchinson Cancer Research Center (FHCRC)
between July 1, 1988, andOctober 1, 2008.Theprotocol
was approved by the FHCRC institutional review board
(IRB). All patients signed consent forms approved by the
IRB. Results are reported as of October 1, 2009.
Patient characteristics are listed inTable 1.Theme-
dian age of patients was 49 years (range: 40-68 years).
The ethnic and racial representation was 5 Hispanic/
Latino, 2 Asian, 15 White, and 1 multiple race. The
pretransplant performance status was not formally
documented. Four patients had infections because of in-
vasive fungal, Gram-negative bacterial, or viral patho-
gens within 1 month before the start of conditioning,
requiring hospitalization for treatment (Table 2). The
conditioning regimen consisted of intravenous (i.v.)
Cy, 50 mg/kg/day given for 4 consecutive days, and
i.v. horse ATG (ATGAM), 30 mg/kg/day given 12
hours after eachof thefirst 3Cydoses (basedonadjusted
ideal body weight). Two patients did not receive ATG,
1 because of a positive skin test, indicating severe
allergy, and 1 because of drug unavailability. BM
was infused 36 hours after the last dose of Cy. Two
patients received granulocyte-colony stimulating factor(G-CSF) mobilized donor peripheral blood stem cells
(PBSCs). For patient number (PN) 15, PBSCs were
used to facilitate more rapid neutrophil recovery after
transplant, because the patient had progressive pulmo-
nary aspergillosis before the transplant. PN 17 received
Cy 1 ATG and 2 Gray total body irradiation (TBI)
conditioning andPBSCs because he had late graft rejec-
tion after the first Cy 1 ATG HCT given 9 months
earlier, at the ageof39years, fromthe samedonor. Stan-
dardMTX/CsAwas given as previously reported [2,16].
If there was no evidence of graft-versus-host disease
(GVHD), CsA prophylaxis was discontinued at 6
months after HCT. All patients received post-HCT
prophylaxis for bacterial, fungal, and viral organisms
and were monitored as per current FHCRC standard
practice.
Donor chimerismwas evaluated in either peripheral
bloodTcells andgranulocytes, or in nucleatedBMcells
on approximately day 80 and/or 1 year afterHCTusing
polymerase chain reaction-based amplification of
variable-number tandem repeat or short-tandem repeat
sequences unique to donors and recipients, or by fluo-
rescein in situ hybridization for X and Y chromosomes
in caseswhenpatients anddonorswere sexmismatched.
Mixed chimerism was defined as .5% and \95%
donor chimerism in at least 1 cell lineage.
Median, range, and proportions were used to sum-
marize descriptive data, as appropriate. OS was esti-
mated using the Kaplan-Meier method with time to
death as the primary outcome and censoring at last
follow-up. Probabilities of acute and chronic GVHD
(aGVHD, cGVHD), time to discontinuation of immu-
nosuppression, and rejection were calculated using
cumulative incidence estimates. Time to the event of
interest was the primary outcome. Death was treated
Table 2. Relevant Clinical Data for SAA Patients after HCT
Patient
Number (PN)
Age
(Years)
Infused
Cell Dose
TNC  108/kg
aGVHD Day
Onset/Grade
cGVHD
(Day of Onset)
Duration of IST
Post- HCT (Months)
Fluid Overload
(Day of Onset)
Pneumonia
(Day of Onset)
Bacteremia
(Day of Event)
% Donor Chimerism
(day +80)
Outcome
(Day/Year of Last
Follow-up after HCT)
1 46 3.11 +16 / III +107 until death — +152 +94 99 BM Death (d+179)
2 46 3.56 NE NE until death +1 — — NE Death (d+3)
3 42 2.18 — — 6 — — — NA CR (19.2 yr)
4 42 1.67 — — 6 23 +220 — 98 BM CR (16.2 yr)
5 40 4.36 NE NE until death 23 — 27 NE Death (d+6)
6* 51 1.31* +80* / II — 9.3 — — — 100 BM* CR (16.2 yr)
7 48 1.92 — — 6 — — — 75 BM CR (15.1 yr)
8 41 2.18 — — 6.5 — — — 90 BM (1 yr) CR (15.0 yr)
9 59 1.96 +25 / II NE until death — +76 +45, +65 NA Death (d+83)
10 49 2.71 +43 / II +119 until death — — +147 NA Death (d+223)
11 55 1.85 +19 / II — 7.5 — — — 100 BM CR (14.1 yr)
12 45 2.36 +69 / II — 6 — +256 — 100 BM CR (8.1 yr)
13 56 4.84 — +85 92 — — — 99.5 BM CR (12.9 yr)
14 59 2.30 +24 / II +92 23 — — +32, +210 100 BM CR (9.1 yr)
15† 53 8.74† NE NE until death 21 212 — NE Death (d+2)
16 42 4.60 — — 6 — — — 59.5 CD3 CR (7.0 yr)
17† 40 22.34† — +162 80 0 — — 100 BM (1 yr) CR (6.7 yr)
18 52 1.68 — — 6 — — 212 95-99 CD3 CR (7.2 yr)
19 63 2.37 +41 / II +258 64 — — +51, +67 85 CD3 CR (6.3 yr)
20 57 2.45 — — 6 — +10 — 67 CD3 CR (5.0 yr)
21 49 2.25 NE NE until death — 222, +14 217, 24 NE Death (d+20)
22 68 2.05 NE NE until death 0 25 +8 NE Death (d+11)
23 50 1.85 +24 / II — 7 — — — 18 CD3 CR (0.9 yr)
1 yr indicates donor chimerism at 1 year after HCT (was not assessed at day 80); aGVHD/cGVHD, acute/chronic graft-versus-host disease; BM, bonemarrow chimerism; CD3, T cell chimerism (sorted from peripheral
blood) and was performed only for PN 16, 18, 19, 20, and 23; CR, complete remission (and alive); HCT, hematopoietic cell transplantation; IST, immunosuppressive therapy for treatment of GVHD; NA, not assessed;
NE, not evaluable; SAA, severe aplastic anemia; TNC, total nucleated cells.
Day 0 is the day of the HCT infusion.
Donor chimerism was assessed by X or Y chromosome FISH probes or donor specific short-tandem repeat sequence PCR analysis. Donor CD33 chimerism at day 80 was 100% for PN 18, 19, 20, and 23 and was 98%
for PN 16.
*PN 6 had graft rejection on day +28 after first HCT (this was considered the primary outcome after HCT); a third HCTwas successfully performed from the same donor 75 days after first HCT. PN 6 developed
aGVHD on day +80 after third HCTand had complete donor chimerism.
†PN15 and PN17 received G-CSF-mobilized peripheral blood stem cells.
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1414 Biol Blood Marrow Transplant 16:1411-1418, 2010D. Sangiolo et al.as a competing risk event for all outcomes; in addition,
graft rejection was a competing risk for GVHD and
discontinuation of immunosuppression [19]. Associa-
tions of pretransplant risk groups with survival were
evaluated using log-rank tests. All reported P-values
are 2-sided, with a significance level of .05.RESULTS
Engraftment
Outcomes after HCT are summarized in Table 2,
which lists patients by PN in chronological order. The
overall rate of graft rejection was 4.3%. Seventeen of
18 patients who survived beyond 3 weeks after HCT
showed sustained engraftment, documented by in-
creasing blood cell counts and BM cellularity, and by
assessment of donor chimerism. The absolute neutro-
phil count surpassed 500/mL at a median of 24 (17-28)
days after HCT. One patient (PN 6) had graft rejec-
tion by day 28 after HCT after infusion of BM with
a total nucleated cell (TNC) cell dose of 1.31  108/
kg. A second HCT from the same donor with Cy 1
ATG reconditioning failed. Sustained engraftment
was established after a third HCT from the same
donor following reconditioning with a CD3-specific
monoclonal antibody combined with high-dose
methylprednisolone [20].
Donor chimerism was assessed on day 80 after
HCT in 13 patients (Table 2). The median donor
chimerism was 99.5% (range: 75%-100%) in BM
(n 5 8) and 100% (range: 98%-100%) in CD33 gran-
ulocyte PBSCs (n5 5). The median CD3 T cell donor
chimerism was 67% (range: 18-99%, n 5 5). Mixed
chimerism was seen in 38% of evaluable patients.
Donor chimerism increased at 1 year after HCT in
all evaluable mixed chimeras.GVHD
Eight patients (35%) developed grades II (30.4 %)
and III (4.3%) aGVHD; the median onset of aGVHD
was day 25 (16-69) after the first HCT (Table 2 and
Figure 1a). Grade IV GVHD was not observed.
aGVHD improved in all patients after treatment with
methylprednisolone and continued administration of
CsA. In addition, 2 patients received beclomethasone
and budesonide for GVHD treatment. The gastroin-
testinal tract was affected by aGVHD in 7 cases.
The cumulative incidence of cGVHD at 2 years
afterHCTwas 26%, with onset requiring systemic im-
munosuppressive treatment at amedian of 3.7 (2.8–8.5)
months after HCT (Table 2 and Figure 1b). The
median time to discontinuation of immunosuppressive
treatment afterHCTwas 6.2 (5.9–92.0)months among
the patients who were able to discontinue immunosup-
pression before death or rejection (Figure 1c).Causes of Death/Fatal Infections
Five patients (22%) died before engraftment
between days 12 and 120 after HCT (Table 2). PN
15 died on day12 because of preexisting disseminated
invasive aspergillosis. PN 2 developed progressive pul-
monary edema during conditioning coincident with
a central venous catheter infection and fever on day
23, and died with cardiac tamponade on day 13.
PN 5 developed Klebsiella bacteremia on day 27, pul-
monary edema during conditioning, followed by mul-
tiorgan failure; she died on day 16, and the autopsy
showed disseminated candidiasis. PN 22 had recur-
rence of an incompletely treated Klebsiella pneumonia
on day 25, developed septic shock with Staphylococcus
aureus on day 18, and died on day 111. PN 21 who
had common variable immunodeficiency before the
diagnosis of SAA, developed progressive invasive
pulmonary aspergillosis and cytomegalovirus (CMV)
pneumonia 3 weeks before HCT, and died on day
120 with acute respiratory distress syndrome and
Burkholderia cepacia pneumonia. Two of these 5
patients had received 6 to 9 months of prednisone,
CsA, and ATG before HCT.
The 4 patients who had documented infections
because of invasive fungal, Gram-negative bacterial or
viral pathogens within 1 month before the start of
conditioning died within 20 days after HCT. With
the exception of PN 18, who developed a coagu-
lase-negative Staphylococcus epidermidis central venous
catheter infection on day 212, none of the 18 pa-
tients surviving beyond day 120 had significant infec-
tions during the month before HCT. Thus,
documented invasive fungal, bacterial, or viral pneu-
monia or Gram-negative bacteremia within 1 month
before HCT was significantly associated with risk of
early traeatment-related mortality, P \ .001 (log-
rank test). In addition, there were 4 patients with
documented bacteremia or invasive fungal infection
successfully treated more than 1 month before
HCT. None of these 4 patients died after HCT.
We found no association between duration of AA
before HCT and mortality after HCT.
Three patients died on days 83, 179, and 223 after
HCT, respectively. PN 9 died from respiratory syncy-
tial virus (RSV) pneumonia and adenovirus nephritis
that developed during prednisone treatment for
aGVHD. PN 1 died with a mixed Pseudomonas aerugi-
nosa and CMV pneumonia during immunosuppressive
treatment for cGVHD. PN10 died with polymicrobial
sepsis associated with severe cGVHD.OS
With a median follow-up of 9.1 years (range for
surviving patients: 0.9-19.2 years), OS was 65% at 10
years after HCT (Figure 1d). All 15 surviving patients
remain in complete remission of SAA with normal
Figure 1. (A) Cumulative incidence and onset of aGVHD (30.4% grade
II, 4.3% grade III). (B) Cumulative incidence and onset of cGVHD (26%).
(C) Upper curve shows declining proportion of patients continuing
Biol Blood Marrow Transplant 16:1411-1418, 2010 1415Allogeneic BMT for Aplastic Anemia Patients Age . 40 yearsblood cell counts, and do not require transfusion or
G-CSF support. No deaths have occurred beyond
day 223 after HCT. OS was 79% when patients with
documented active or progressive fungal, bacterial,
or viral pneumonia or Gram-negative bacteremia
within 1 month before conditioning for HCT were
excluded.Nonfatal Infections
Seven patients (30%) had significant but nonfatal
infections after HCT (Table 2). Invasive aspergillus
pneumonia was diagnosed in 1 patient on day 110.
Four patients developed bacteremia with Gram-
positive cocci on days 132, 145, 167, and 1147,
respectively; a second episode occurred in 1 patient
at 7 months after HCT. Three patients developed
bacteremia with Gram-negative rod organisms on
days 151, 165, and 194, respectively, concurrent
with treatment for gastrointestinal aGVHD. One
patient was diagnosed with mycoplasma pneumonia
at 1220 days after HCT. All of these infections were
successfully treated.CMV Reactivation
Eleven patients (50% of those at risk) had CMV
reactivation detected by testing for antigen or DNA,
with onset between 24 and 256 (median, 57) days after
HCT. Two patients developed CMV pneumonia on
days 152 and 256 after HCT, respectively (Table 2).
Ten of 11 patients (91%) with CMV reactivation
after HCT had complete resolution with antiviral
treatment.Fluid Overload
Six patients (26%) developed fluid overload requir-
ing specific medical treatment either during the condi-
tioning regimen or within the first week after HCT
(Table 2). Three deaths early after HCT were associ-
ated with concurrent pretransplant infections (PN 5,
15, and 22) as described earlier; clinical or autopsy
findings were not consistent with Cy-induced cardio-
toxicity. Two patients developed transient diffuse
pulmonary edema during ATG andHCT infusion, re-
spectively. For both patients, contemporaneous echo-
cardiograms showed normal left ventricular ejection
fraction, and symptoms resolved with treatment. As
described before, PN 2 developed pulmonary edema
and cardiac tamponade and died on day 13. Anpostgrafting IST, lower curve shows cumulative incidence of death or
rejection while on immunosuppression therapy. Area between curves
represents proportion of patients who are alive, rejection free, and on
immunosuppression therapy. (D) OS after HLA-identical HCT for
SAA for all patients (n 5 23) over 40 years of age (65% survival at 10
years). Tick marks indicate time of last follow-up.
1416 Biol Blood Marrow Transplant 16:1411-1418, 2010D. Sangiolo et al.autopsy was not obtained. Cy-induced cardiotoxicity
could not be excluded as a possible cause of death.
Delayed Posttransplant Complications
Three patients (PN 11, 14, 13) developed avascular
bone necrosis at 2, 3, and 9 years after HCT, respec-
tively. The first patient had received a total of 6months
of prednisone treatment and the next 2 patients
received immunosuppressive treatment for 23 and 77
months after HCT, respectively. Three patients (PN
3, 11, and 13) developed superficial basal cell carcino-
mas with successful resection at 5.5, 8.7, 8.8, and
15 years after HCT, respectively.DISCUSSION
Allogeneic HCT provides curative therapy for
patients with SAA, but many transplant centers restrict
its application to patients younger than 40 years of age
because of concerns about toxicity of the Cy 1 ATG
conditioning regimen and the risk of GVHD. Our
retrospective study clearly indicates that HCT from
HLA-matched sibling donors can be successfully ex-
tended to SAA patients older than 40 years (the median
age of patients in this studywas 49 years).However, sys-
temic infections at the time of HCT identify poor-risk
candidates with a very high risk of early mortality.
The observed long-term OS of 65% at 10 years
compares very favorably with recently published
results for SAA patients treated with IST, where
long-term survival in patients above 50 years of age
was less than 40% [9]. The current results are particu-
larly significant because preceding IST had been
unsuccessful in 48% of our patients.
A survival benefit in favor of HCT over IST was
consistently observed in historical studies of SAA
patients, but this benefit was limited to patients youn-
ger than age 40 years. Older SAA patients had equiva-
lent or worse OS after HCT compared to IST [16,17].
These observations were likely influenced by the fact
that many patients did not receive what is now
considered the optimal transplant conditioning with
Cy 1 ATG and postgrafting GVHD prophylaxis
with MTX 1 CsA.
A recent multicenter EBMT study of HCT with
HLA-identical sibling donors showed an OS rate of
71% with a median follow-up of 4 years after a Flu-
based conditioning regimen in 21 SAA patients .40
years of age [18]. OS was 60% at 5 years among 239
SAA patients.30 years of age who receiving the stan-
dard conditioning regimen of Cy 200 mg/kg with or
without ATG. Despite the improved survival outcome
compared to historical studies, concern persisted that
the conventional Cy 200 mg/kg-based conditioning
regimen may cause excessive toxicity in older SAA pa-
tients. It is unclear, however, whether the Flu-basedregimen is superior to Cy 1 ATG, because patients
in the EBMT study were not randomized between
the treatment arms. In addition, most patients did
not receive ATG with Cy, 34% received mobilized
blood cell grafts, and the postgrafting immunosup-
pressive regimen was not uniform.
In our current study, the incidence of graft rejec-
tion was low. One patient had primary graft rejection
but had sustained engraftment after a third HCT,
and 1 patient had secondary graft rejection at age 39
years and had successful second HCT at age 40 years
(for which data are shown). Graft rejection was previ-
ously associated with transfusions given before HCT.
Although all patients had received multiple transfu-
sions before HCT, nearly all of these blood products
had been depleted of leukocytes or irradiated [21,22].
The median time from diagnosis to HCT was 3
months, which may have also contributed to the
observed low incidence of graft rejection.
Mixed hematopoietic chimerism at 80 days after
HCT was not associated with graft rejection. Thirty-
eight percent of evaluable patients had mixed chime-
rism at day 80, and all mixed chimeras had a subsequent
increase in donor chimerism. There may have been
additional patients with mixed T cell chimerism
among those with .95% donor BM chimerism, but
prior to March 2001 PB T cell chimerism was not
routinely assessed.
The observed cumulative incidences of aGVHD
and cGVHD in our study (35% and 26%, respectively)
were comparable to that reported previously in studies
with younger patients with SAA [6]. Furthermore, the
incidence of grade III GVHDwas only 4.3% and grade
IVGVHDwas not observed. It is very likely that the use
ofATGduringconditioningpreventedbothgraft rejec-
tion and GVHD. In most cases, GVHD responded
promptly to a short course of prednisone therapy.
The most striking finding in this study was that an
active infection within 1 month before HCT, whether
because of a Gram-negative bacterial, a fungal, or a vi-
ral pathogen, was associated with early death after
HCT. The OS at 10 years for patients without docu-
mented pneumonia or Gram-negative bacteremia
during the month before HCT was 79%. Patients
with a history of infection successfully treated more
than 1 month before HCT were not at an increased
risk for early mortality after HCT. These findings sug-
gest that to reduce the risk of early death after HCT,
SAA patients should either proceed to HCT before
onset of pneumonia or Gram-negative bacteremia, or
delay HCT until infection has completely resolved.
On the other hand, the primary reason for proceeding
to HCT with an active infection was the concern that
infection would be fatal unless hematopoietic function
could be restored. Our results support the findings of
retrospective studies, which showed that patients
with invasive fungal infections or RSV infections
Biol Blood Marrow Transplant 16:1411-1418, 2010 1417Allogeneic BMT for Aplastic Anemia Patients Age . 40 yearswithin the month before HCT have an increased risk
of mortality [23]. In addition, severe neutropenia prior
to HCT in patients with myelodysplastic syndrome
was associated with increased infectious mortality after
HCT [24].
We observed that 26% of patients developed pul-
monary edema or fluid overload between days 23 to
11. Detailed review suggested that this complication
was exacerbated primarily by concurrent systemic in-
fection and was not directly because of Cy-induced
cardiomyopathy. The development of systemic infec-
tion immediately before HCT was associated with
a high risk of fatal cardiopulmonary toxicity during
or after conditioning. Careful cardiac screening before
transplantation and frequent monitoring of fluid status
during and after administration of Cy 1 ATG might
help to minimize the risk of toxicity, especially in older
patients.
The incidence of second malignancies (3 cases of
basal cell carcinoma) in our older cohort was not
significantly higher than that observed in younger
patients [4]. Although basal cell carcinoma is not
a life-threatening complication, the data reinforce
the need to monitor patients for second malignancies
after HCT. Our results provide further support for
HCT as treatment for SAA, because nontransplant
IST is associated with a higher risk of developing fatal
subsequent malignancies, particularly in older patients
[9]. The 3 cases of avascular hip necrosis emphasize the
need to improve the prevention and treatment of
GVHD and to reduce the duration of steroid-based
treatment.
In conclusion, although this was a retrospective
study that included several patients that were trans-
planted more than 15 years ago, our results suggest
that older patients with AA who have an HLA-
matched sibling andwhoarewithout significantmedical
comorbidities should proceed to BM transplantation
promptly for definitive curative therapy. Patients who
have compromised clinical conditions such as cardio-
myopathy or systemic infection during the month
before HCT are not suitable candidates for the use of
Cy 1 ATG as a conditioning regimen. A history of
active or very recent infections adversely affects HCT
outcome and should be taken into accountwhenmaking
treatment decisions for older patients with SAA.ACKNOWLEDGMENTS
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